

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangsu Recbio Technology Co., Ltd.**  
**江蘇瑞科生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2179)**

**INSIDE INFORMATION ANNOUNCEMENT**  
**ISSUANCE OF FILING NOTICE BY THE CSRC FOR**  
**THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

Reference is made to the announcement dated May 21, 2025 of the Company (the “**Announcement**”) in relation to, among others, the proposed participation in the H Share Full Circulation by the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that the Company has received a filing notice dated January 13, 2026 (the “**Filing Notice**”) issued by the CSRC to the Company in respect of the H Share Full Circulation recently. Pursuant to the Filing Notice, the Company has completed the filing with the CSRC in respect of the conversion into H shares of an aggregate of 141,953,489 unlisted shares held by 28 shareholders. The Filing Notice is valid for 12 months commencing from January 13, 2026. The Company will apply to the Stock Exchange for approval for the listing of, and permission to deal in, the relevant H shares. The details of the names of shareholders and number of shares subject to conversion under the H Share Full Circulation are as follows:

No.	Name of shareholder	Class of share	Shareholding		Number of shares proposed for full circulation (share)	Percentage of full circulation in unlisted shares held
			Number of unlisted shares	percentage of unlisted shares (share)		
1	LIU Yong	Domestic shares	193,943	0.0310%	193,943	100.00%
2	Taizhou Yuangong Technology Partnership (Limited Partnership)	Domestic shares	62,147,715	9.9265%	62,147,715	100.00%
3	Taizhou Ruibaitai Pharmaceutical Technology Partnership (Limited Partnership)	Domestic shares	8,076,923	1.2901%	8,076,923	100.00%

No.	Name of shareholder	Class of share	Number of unlisted shares (share)	Shareholding percentage of unlisted shares	Number of shares proposed for full circulation (share)	Percentage of full circulation in unlisted shares held
4	Taizhou Baibei Biotechnology Partnership (Limited Partnership)	Domestic shares	1,143,750	0.1827%	1,143,750	100.00%
5	Taizhou Guquan Biotechnology Partnership (Limited Partnership)	Domestic shares	1,143,750	0.1827%	1,143,750	100.00%
6	Beijing Junlian Shengyuan Equity Investment Enterprise (Limited Partnership)	Domestic shares	7,084,855	1.1316%	7,084,855	100.00%
7	Zhuhai Junlian Yongshuo Equity Investment Enterprise (Limited Partnership)	Domestic shares	3,380,400	0.5399%	3,380,400	100.00%
8	Shenzhen Fuhai Juanyong II Venture Capital Enterprise (Limited Partnership)	Domestic shares	5,452,020	0.8708%	1,817,340	33.33%
9	Shenzhen Fuhai Juanyong III Venture Capital Enterprise (Limited Partnership)	Domestic shares	1,038,460	0.1659%	346,153	33.33%
10	Shenzhen Qianhai Kekong Fuhai Youxuan Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	991,275	0.1583%	330,425	33.33%
11	Shenzhen Fuhai Youxuan II High Technology Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	692,310	0.1106%	230,770	33.33%
12	Shenzhen Nanshan OFC Small and Medium Venture Capital Investment Fund Partnership (Limited Partnership)	Domestic shares	495,640	0.0792%	165,213	33.33%
13	Shenzhen Yingkejin Investment Management Partnership (Limited Partnership)	Domestic shares	4,525,393	0.7228%	4,525,393	100.00%
14	Liuyang Woyang Health Industry Investment Partnership (Limited Partnership)	Domestic shares	2,081,680	0.3325%	2,081,680	100.00%
15	Changsha Woyang Phase II Health Industry Investment Partnership (Limited Partnership)	Domestic shares	2,031,287	0.3244%	2,031,287	100.00%
16	Shenzhen Luewei Investment Management Partnership (Limited Partnership)	Domestic shares	429,553	0.0686%	429,553	100.00%
17	Shenzhen Hanchen Venture Capital Investment Fund Partnership (Limited Partnership)	Domestic shares	8,962,500	1.4315%	4,481,250	50.00%

No.	Name of shareholder	Class of share	Number of unlisted shares (share)	Shareholding percentage of unlisted shares	Number of shares proposed for full circulation (share)	Percentage of full circulation in unlisted shares held
18	Ningbo Meishan Bonded Port Areas Haojin Zhitong Venture Capital Investment Partnership (Limited Partnership)	Domestic shares	2,645,927	0.4226%	2,645,927	100.00%
19	Ganzhou Haojin Zhiyuan Equity Investment Center (Limited Partnership)	Domestic shares	2,164,947	0.3458%	2,164,947	100.00%
20	Nanjing Tsingsong Medical Health Industry Investment Partnership (Limited Partnership)	Domestic shares	1,758,325	0.2808%	1,758,325	100.00%
21	Shenzhen Tsingsong Chengtou Investment Partnership (Limited Partnership)	Domestic shares	1,383,325	0.2210%	1,383,325	100.00%
22	Wuhan Chengyelian Equity Investment Enterprise (Limited Partnership)	Domestic shares	2,551,150	0.4075%	2,551,150	100.00%
23	Guangdong Yifang Tengda Equity Investment Partnership (Limited Partnership)	Domestic shares	1,250,000	0.1997%	1,250,000	100.00%
24	Yifang Huida Venture Capital (Guangdong) Investment Partnership (Limited Partnership)	Domestic shares	1,250,000	0.1997%	1,250,000	100.00%
25	Jiangsu Taizhou Guangkong Industry Investment Partnership (Limited Partnership)	Domestic shares	991,275	0.1583%	991,275	100.00%
26	Springleaf Investments Pte. Ltd.	Unlisted foreign shares	12,000,000	1.9167%	12,000,000	100.00%
27	Shanghai Jiyue Enterprise Management Partnership (Limited Partnership)	Domestic shares	8,318,800	1.3287%	8,318,800	100.00%
28	Shanghai Jixuan Enterprise Management Consulting Partnership (Limited Partnership)	Domestic shares	8,029,340	1.2825%	8,029,340	100.00%
<b>Total</b>		-	<b>152,214,543</b>	<b>24.3125%</b>	<b>141,953,489</b>	-

As of the date of this announcement, the details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

**The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Jiangsu Recbio Technology Co., Ltd.**  
**Mr. XU Haoyu**  
*Chairman*

Jiangsu Province, the PRC, January 30, 2026

*As at the date of this announcement, the Board comprises Mr. XU Haoyu as the Chairman of the Board and a non-executive director, Dr. LIU Yong, Mr. WEI Qifang and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.*